Literature DB >> 19205661

On track to limit antifungal overuse!

Philippe Eggimann, Frédéric Lamoth, Oscar Marchetti.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19205661     DOI： 10.1007/s00134-009-1432-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  17 in total

Review 1.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

2.  Management of central venous catheters in patients with cancer and candidemia.

Authors:  Issam Raad; Hend Hanna; Maha Boktour; Essam Girgawy; Hadi Danawi; Masoud Mardani; Dimitrios Kontoyiannis; Rabih Darouiche; Ray Hachem; Gerald P Bodey
Journal:  Clin Infect Dis       Date:  2004-03-26       Impact factor: 9.079

3.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

Review 4.  Risk of resistance associated with fluconazole prophylaxis: systematic review.

Authors:  Luc P Brion; Smart E Uko; David L Goldman
Journal:  J Infect       Date:  2007-01-18       Impact factor: 6.072

5.  Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies.

Authors:  Maura Prella; Jacques Bille; Mauro Pugnale; Bertrand Duvoisin; Matthias Cavassini; Thierry Calandra; Oscar Marchetti
Journal:  Diagn Microbiol Infect Dis       Date:  2005-02       Impact factor: 2.803

Review 6.  Management of Candida species infections in critically ill patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-12       Impact factor: 25.071

7.  Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

Authors:  Elizabeth Johnson; Ana Espinel-Ingroff; Adrien Szekely; Hans Hockey; Peter Troke
Journal:  Int J Antimicrob Agents       Date:  2008-09-13       Impact factor: 5.283

Review 8.  Antifungals in the ICU.

Authors:  Elliott Geoffrey Playford; Philippe Eggimann; Thierry Calandra
Journal:  Curr Opin Infect Dis       Date:  2008-12       Impact factor: 4.915

9.  Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; J F Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

10.  1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.

Authors:  Laurence Senn; James Owen Robinson; Sabine Schmidt; Marlies Knaup; Nobuo Asahi; Shinji Satomura; Shuuji Matsuura; Bertrand Duvoisin; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079
View more
  3 in total

Review 1.  Fungal infections in burns: a comprehensive review.

Authors:  M F Struck; J Gille
Journal:  Ann Burns Fire Disasters       Date:  2013-09-30

2.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Diagnosis of invasive candidiasis in the ICU.

Authors:  Philippe Eggimann; Jacques Bille; Oscar Marchetti
Journal:  Ann Intensive Care       Date:  2011-09-01       Impact factor: 6.925
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.